Clinical Trial
Clinical Trials Information
An Open-Label, Non-Randomized, Phase I, Prospective, Dose-finding Study to Evaluate the Safety and Clinical Activity of GF-CART01 (CD20/19 CAR T cell) in Subjects with Relapsed orRefractory B-Cell Hematological Malignancies.
- Location: Taiwan(NTUH)
- Status: Recruiting
- Study Population(Indication): Diffuse Large B-cell Lymphoma(DLBCL), Follicular Lymphoma((FL, Primary Mediastinal Large B-Cell Lymphoma(PMLBCL), or High Grade B-Cell Lymphoma(HGBCL)